Ensysce Biosciences (ENSCW) Net Income towards Common Stockholders (2018 - 2025)

Ensysce Biosciences (ENSCW) has 8 years of Net Income towards Common Stockholders data on file, last reported at -$3.7 million in Q3 2025.

• Net Income towards Common Stockholders for Q3 2025 came in at -$3.7 million, down 663.51% year-over-year; the trailing twelve-month figure through Dec 2025 was -$7.4 million (up 7.25% YoY), and the FY2024 annual result was -$8.0 million, up 24.83% from the prior year.
• Net Income towards Common Stockholders eased to -$3.7 million in Q3 2025 per ENSCW's latest filing, from -$1.7 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $661769.0 in Q3 2024 and troughed at -$17.2 million in Q3 2021.
• A 5-year average of -$4.3 million and a median of -$2.7 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2021 and 2024: Net Income towards Common Stockholders slumped 5165.56% in 2021, then jumped 124.61% in 2024.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$10.8 million in 2021, then surged by 49.06% to -$5.5 million in 2022, then jumped by 36.54% to -$3.5 million in 2023, then dropped by 1.72% to -$3.6 million in 2024, then retreated by 4.62% to -$3.7 million in 2025.
• Business Quant data shows ENSCW's Net Income towards Common Stockholders at -$3.7 million in Q3 2025, -$1.7 million in Q2 2025, and -$1.9 million in Q1 2025.